The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
Open accessAbstract
The immune system is critical in modulating cancer progression, but knowledge of immune composition, phenotype, and interactions with tumor is limited. We used multiplexed ion beam imaging by time-of-flight (MIBI-TOF) to simultaneously quantify in situ expression of 36 proteins covering identity, function, and immune regulation at sub-cellular resolution in 41 triple-negative breast cancer patients. Multi-step processing, including deep-learning-based segmentation, revealed variability in the composition of tumor-immune populations across individuals, reconciled by overall immune infiltration and enriched co-occurrence of immune subpopulations and checkpoint expression. Spatial enrichment analysis showed immune mixed and compartmentalized tumors, coinciding with expression of PD1, PD-L1, and IDO in a cell-type- and location-specific manner. Ordered immune structures along the tumor-immune border were associated with compartmentalization and linked to survival. These data demonstrate organization in the tumor-immune microenvironment that is structured in cellular composition, spatial arrangement, and regulatory-protein expression and provide a framework to apply multiplexed imaging to immune oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nuclear segmentation was performed with DeepCell (Van Valen et al., 2016) (https://github.com/vanvalenlab/deepcell-tf) as previously described (Keren et al., 2018), using in-house training and validation MIBI imaging datasets from a variety of human clinical tissue types to ensure reproducibility.”
From Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma (2020) · cites this paper as Keren et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883 · cited 1×
“Since H3K9ac was shown to be correlated with open chromatin and H3K27me3 with closed chromatin (Kouzarides, 2007), these global changes in their ratios may indicate that cells on the tumor border are more transcriptionally active than those in the tumor center.”
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., den Eynden, G. V., Baehner, F. L., Penault-Llorca, F. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,142
Spatially resolved, highly multiplexed RNA profiling in single cells
Chen, K. H., Boettiger, A. N., Moffitt, J. R., Wang, S., & Zhuang, X. (2015) · Science · doi:10.1126/science.aaa6090 · Cited by 2,969
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Bendall, S. C., Simonds, E. F., Qiu, P., Amir, E.-A. D., Krutzik, P. O., Finck, R., Bruggner, R. V., Melamed, R., Trejo, A., Ornatsky, O. I., et al. (2011) · Science · doi:10.1126/science.1198704 · Cited by 2,279
Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry
Giesen, C., Wang, H. A. O., Schapiro, D., Zivanovic, N., Jacobs, A., Hattendorf, B., Schüffler, P. J., Grolimund, D., Buhmann, J. M., Brandt, S., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2869 · Cited by 1,951
FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry data
Gassen, S. V., Callebaut, B., van Helden, M. J. G., Lambrecht, B. N., Demeester, P. M. A., Dhaene, T., & Saeys, Y. (2015) · Cytometry Part A · doi:10.1002/cyto.a.22625 · Cited by 1,930
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb‐Esfahani, S., Kronenwett, R., Hanusch, C. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,796
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,762
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · cited 1×
“Although preliminary, overall response rates typically range 15–30%, similar to observations in gastric and head and neck cancers (Muro et al., 2016; Seiwert et al., 2016).”
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,494
Topographic distance and watershed lines
Meyer, F. (1994) · Signal Processing · doi:10.1016/0165-1684(94)90060-4 · Cited by 1,447
Burstein, M. D., Tsimelzon, A. I., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,442
Classifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,436
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D. V. T., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B. A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,125
Multiplexed ion beam imaging of human breast tumors
Angelo, M., Bendall, S. C., Finck, R., Hale, M. B., Hitzman, C., Borowsky, A. D., Levenson, R. M., Lowe, J. B., Liu, S. D., Zhao, S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3488 · Cited by 1,108
An Immune Atlas of Clear Cell Renal Cell Carcinoma
Chevrier, S., Levine, J., Zanotelli, V. R., Siliņa, K., Schulz, D., Bacac, M., Ries, C. H., Ailles, L., Jewett, M. A. S., Moch, H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.016 · Cited by 1,036
LAG 3 ( CD 223) as a cancer immunotherapy target
Andrews, L. P., Marciscano, A. E. E., Drake, C. G., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 980
Highly Multiplexed Subcellular RNA Sequencing in Situ
Lee, J. H., Daugharthy, E. R., Scheiman, J., Kalhor, R., Yang, J. L., Ferrante, T. C., Terry, R., Jeanty, S. S. F., Li, C., Amamoto, R., et al. (2014) · Science · doi:10.1126/science.1250212 · Cited by 973
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
Denkert, C., Liedtke, C., Tutt, A. N. J., & von Minckwitz, G. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32454-0 · Cited by 897
Van Valen, D. A., Kudo, T., Lane, K. M., Macklin, D. N., Quach, N. T., DeFelice, M. M., Maayan, I., Tanouchi, Y., Ashley, E. A., & Covert, M. W. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005177 · Cited by 557
Immunohistochemistry as an Important Tool in Biomarkers Detection and Clinical Practice
Matos, L. L., Trufelli, D. C., de Matos, M. G. L., & Pinhal, M. A. D. S. (2010) · Biomarker Insights · doi:10.4137/bmi.s2185 · Cited by 442
Combination immunotherapy: a road map
Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M., & Wolchok, J. D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0218-5 · Cited by 389
Temporal Analysis of Early Immune Responses in Patients With Acute Hepatitis B Virus Infection
Dunn, C., Peppa, D., Khanna, P., Nebbia, G., Jones, M., Brendish, N. J., Lascar, R. M., Brown, D. J., Gilson, R. J. C., Tedder, R. S., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.054 · Cited by 378
Biomarkers of response to PD-1/PD-L1 inhibition
Vareki, S. M., Garrigós, C., & Durán, I. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.06.001 · Cited by 325
Nirschl, C. J., & Drake, C. G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1972 · Cited by 322
Checkpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from here
Kwa, M. J., & Adams, S. (2018) · Cancer · doi:10.1002/cncr.31272 · Cited by 216
André, F., Dieci, M. V., Dubsky, P. C., Sotiriou, C. P., Curigliano, G., Denkert, C., & Loi, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2701 · Cited by 195
Burugu, S., Gao, D., Leung, S. C. Y., Chia, S., & Nielsen, T. O. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx557 · Cited by 193
Minin, G. D., Bellazzo, A., Ferro, M. D., Chiaruttini, G., Nuzzo, S., Bicciato, S., Piazza, S., Rami, D., Bulla, R., Sommaggio, R., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.10.013 · Cited by 165
Enhancement of T cell recruitment and infiltration into tumours
Oelkrug, C., & Ramage, J. M. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12382 · Cited by 143
Huang, W., Hennrick, K. T., & Drew, S. A. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.05.009 · Cited by 136
Yeong, J. P.-S., Thike, A. A., Lim, J. C. T., Lee, B. T. K., Li, H., Wong, S. C., Hue, S. S., Tan, P. H., & Iqbal, J. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4161-4 · Cited by 136
New Immunotherapy Strategies in Breast Cancer
Yu, L., Tang, J., Zhang, C., Zeng, W., Yan, H., Li, M.-P., & Chen, X. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14010068 · Cited by 118
Carrel, S., Schmidt-Kessen, A., & Giuffrè, L. (1985) · European Journal of Immunology · doi:10.1002/eji.1830150204 · Cited by 116
Triple-Negative Breast Cancer: Immune Modulation as the New Treatment Paradigm
Disis, M. L., & Stanton, S. E. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e25 · Cited by 108
Fortis, S. P., Sofopoulos, M., Sotiriadou, N. N., Haritos, C., Vaxevanis, C., Anastasopoulou, E. A., Janssen, N., Arnogiannaki, N., Ardavanis, A. S., Pawelec, G., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0240-7 · Cited by 89
Indoleamine 2,3-dioxygenase, Tregs and Cancer
Munn, D. H. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795656045 · Cited by 81
Dense transcript profiling in single cells by image correlation decoding
Coskun, A. F., & Cai, L. (2016) · Nature Methods · doi:10.1038/nmeth.3895 · Cited by 72
The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?
Troncone, G., & Gridelli, C. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.10.05 · Cited by 32
Cellular dynamics of resolving inflammation
Bagaitkar, J. (2014) · Blood · doi:10.1182/blood-2014-07-589341 · Cited by 12
Research works printed but not linked: 1
- Haralick, 1973, Textural Features for Image Classification. IEEE Trans. Syst. Man. Cybern, SMC, 3, 610
Cited by
Sorted by citations
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Zhang, Y., & Zhang, Z. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,906
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y. Q., & Yu, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 2,026
Exploring tissue architecture using spatial transcriptomics
Rao, A., Barkley, D., França, G. S., & Yanai, I. (2021) · Nature · doi:10.1038/s41586-021-03634-9 · Cited by 1,700
Metadata
- Authors
- Keren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S., Yang, S.-R., Kurian, A., Van Valen, D., West, R., Bendall, S. C., & Angelo, M.
- Affiliations
- Stanford University (US)
- Stanford Medicine (US)
- Corresponding author
- Bendall, Sean C.
- Angelo, Michael
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 174
- Issue
- 6
- Pages
- 1373-1387.e19
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC6132072
- OpenAlex
- W2890156321
- Cited by
- 1,183
- References
- 54
- Citations by year
- 2026: 222 · 2025: 147 · 2024: 141 · 2023: 164 · 2022: 153 · 2021: 167 · 2020: 105 · 2019: 74 · 2018: 9
- FWCI
- 33.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Funders
- Damon Runyon Cancer Research Foundation (DRG-2292-17, DRG-2017-09)
- EMBO Long-Term fellowship (ALTF 1128-2016)
- NIH F32 Postdoctoral Fellowship
- Burroughs Wellcome PDEP award
- The Allen Discovery Center at Stanford University
- Crowdflower A.I.
- NIH (5R01CA18390402, 1DP2OD022550-01, 1-R00-GM104148-01, 5U19AI116484-02, U19 AI104209, 1-DP5-OD019822, 1R01AG056287-01, 1R01AG057915-01, 1U24CA224309-01)
- Bill and Melinda Gates Foundation
- Stanford Cancer Institute (NSF ECCS-1542152)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- triple-negative breast cancer, tumor immune microenvironment, MIBI, immune checkpoint molecules, PD-1, PD-L1, IDO, immune cell infiltration, patient survival
- MeSH terms
- Machine Learning, Lymphocyte Activation Gene 3 Protein, Female, Humans, Lymphocytes, Mass Spectrometry, Antigens, CD, Cluster Analysis, Principal Component Analysis, Indoleamine-Pyrrole 2,3,-Dioxygenase, Kaplan-Meier Estimate, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Spatial Analysis, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
